{
  "consolidation_metadata": {
    "timestamp": "2025-10-02T14:07:57.045729",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 38,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        1
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom docetaxel is the appropriate patient-individual therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        2
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "different chemotherapies without platinum (cisplatin/ carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        3
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "different chemotherapies without platinum (cisplatin/ carboplatin) as well as treatment with an immune checkpoint inhibitor as monotherapy"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel (only for patients with PD-L1 negative tumours)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        4
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel (only for patients with PD-L1 negative tumours)"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        5
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pemetrexed (only for patients with PD-L1 negative tumours and except in case of predominantly squamous histology)"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        6
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells))",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        7
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells))"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        8
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab"
      }
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        9
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel monotherapy",
      "Countries": [
        "DK",
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        10,
        30
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel monotherapy"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "standard of care therapy",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        11
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "standard of care therapy"
      }
    },
    {
      "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        12
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        13
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel plus nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        14
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemotherapy"
      }
    },
    {
      "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapy",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        15
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
        "intervention": "Medicine X (under assessment)",
        "comparator": "immunotherapy"
      }
    },
    {
      "Population": "patients treated with immunotherapy monotherapy in the first line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy based on platinum salts, such as in the 1st line: cisplatin-vinorelbine, cisplatine-citagembine, carboplatin-paclitaxel, cisplain-docetaxel, Cisplatin-pemetrexed (non-epidermoid only)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        16
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients treated with immunotherapy monotherapy in the first line",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemotherapy based on platinum salts, such as in the 1st line: cisplatin-vinorelbine, cisplatine-citagembine, carboplatin-paclitaxel, cisplain-docetaxel, Cisplatin-pemetrexed (non-epidermoid only)"
      }
    },
    {
      "Population": "patients treated with chemotherapeutic therapy + immunotherapies in the line 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapists in the single line: pemetrexed, docetaxel (non-epidermoside only)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        17
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients treated with chemotherapeutic therapy + immunotherapies in the line 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemotherapists in the single line: pemetrexed, docetaxel (non-epidermoside only)"
      }
    },
    {
      "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapeutic treatment is the reference: atezolizumab, nivolumab or pembrolizimab (if PD-L1 ≥ 1%)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        18
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients receiving first line bi-chemotherapy, without immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "immunotherapeutic treatment is the reference: atezolizumab, nivolumab or pembrolizimab (if PD-L1 ≥ 1%)"
      }
    },
    {
      "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        19
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients receiving first line bi-chemotherapy, without immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab"
      }
    },
    {
      "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        20
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients receiving first line bi-chemotherapy, without immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab"
      }
    },
    {
      "Population": "patients receiving first line bi-chemotherapy, without immunotherapy and with PD-L1 ≥ 1%",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        21
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients receiving first line bi-chemotherapy, without immunotherapy and with PD-L1 ≥ 1%",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        22
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        23
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel + nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        24
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pemetrexed"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        25
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        26
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        27
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        28
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "platinum doublet"
      }
    },
    {
      "Population": "tumours expressing PD-L1 with a TPS >=1%",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        29
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "tumours expressing PD-L1 with a TPS >=1%",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation that has progressed after at least one prior systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        31
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation that has progressed after at least one prior systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Sotorasib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        32
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Sotorasib"
      }
    },
    {
      "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        33
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sotorasib"
      }
    },
    {
      "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        34
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "adagrasib"
      }
    },
    {
      "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        35
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        36
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        37
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel plus nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        38
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "adagrasib"
      }
    }
  ]
}